What is the market opportunity for BioXcel in the estimated 23 million annual at-home agitation episodes lacking FDA-approved treatments?

What is the market opportunity for BioXcel in the estimated 23 million annual at-home agitation episodes lacking FDA-approved treatments? AI+
Andrew • 03-25 • BioXcel Therapeutics, Inc. • Public •
US:BTAI

What is the market opportunity for BioXcel in the estimated 23 million annual at-home agitation episodes lacking FDA-approved treatments?

Rate this post:
0
Kommentarer (5)
AI+ Standard • 03-25
Dette svar blev genereret af AI. Selvom vi stræber efter nøjagtighed, kan det indeholde fejl.

BioXcel Therapeutics (BTAI) is targeting a significant market opportunity in at-home agitation episodes with its product, IGALMI (dexmedetomidine sublingual film), also known as BXCL501. The company estimates a total addressable market of 57 to 77 million annual agitation episodes in the U.S. alone for at-home use.1 This revised estimate is substantially higher than previous projections of 23 million episodes, as historical claims data likely underestimated the true frequency due to a lack of approved treatment options in this setting.1

Key aspects of this market opportunity include:

  • Unmet Need: There are currently no FDA-approved acute treatment options for patients experiencing agitation associated with bipolar disorders or schizophrenia in the at-home setting.2 This represents a significant gap in care that BioXcel aims to fill.
  • Product Status: IGALMI is already FDA-approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, for self-administration under healthcare provider supervision.3 BioXcel has completed its SERENITY At-Home pivotal Phase 3 safety trial for the at-home use of IGALMI.3
  • Regulatory Pathway: The company plans to submit a supplemental New Drug Application (sNDA) for the at-home use of IGALMI in early Q1 2026, based on positive data from the SERENITY At-Home trial.1 The trial's results indicated a safety profile consistent with the approved label, with no drug-related serious adverse events or discontinuations due to tolerability in the BXCL501 arm.1
  • Market Potential: BioXcel's market research suggests that agitation episodes occur approximately three times per month in the home setting, further underscoring the large potential market if IGALMI gains approval for this indication.4 While current IGALMI net revenues are relatively modest (e.g., $98 thousand in Q3 2025 for institutional use), approval for at-home use could significantly expand its commercial reach.1

The expansion into the at-home setting could redefine the treatment paradigm for agitation, providing patients with a much-needed option for managing episodes outside of an institutional environment.

Rate this response:
0
Andrew • 03-25

Analyze the specific details of the sNDA submission for IGALMI's at-home use and its potential implications for the FDA review timeline.

AI+ Standard • 03-25
Dette svar blev genereret af AI. Selvom vi stræber efter nøjagtighed, kan det indeholde fejl.

BioXcel Therapeutics (BTAI) is preparing to submit a supplemental New Drug Application (sNDA) in early Q1 2026 for the at-home use of IGALMI (dexmedetomidine sublingual film) for the acute treatment of agitation associated with bipolar disorders or schizophrenia. This submission is a critical step in addressing a significant unmet medical need, as there are currently no FDA-approved acute treatment options for these conditions in the at-home setting.1

The sNDA will leverage positive data from the SERENITY At-Home pivotal Phase 3 safety trial, which successfully met its primary endpoint.2 BioXcel has also engaged with the FDA through pre-sNDA meetings, receiving feedback that suggests the planned regulatory package should be sufficient.2

Given that BXCL501, the active ingredient in IGALMI, has been granted Fast Track designation for agitation associated with schizophrenia, bipolar disorders, and dementia, the FDA review timeline for this sNDA could potentially be expedited.3 Fast Track designation allows for increased interaction with the FDA and may lead to a priority review, which shortens the review period from a standard ten months to six months.4 This potential for an accelerated review could bring the at-home treatment option to market sooner, significantly expanding IGALMI's commercial reach beyond its current institutional approval.1 The company's updated market research indicates a total addressable market of 57 to 77 million annual agitation episodes in the U.S. for at-home use, underscoring the substantial opportunity.1

Rate this response:
1
Andrew • 03-25

Research historical FDA sNDA review timelines for Fast Track designated products in neuroscience to project a potential approval date for IGALMI's at-home use.

AI+ Standard • 03-25
Dette svar blev genereret af AI. Selvom vi stræber efter nøjagtighed, kan det indeholde fejl.

BioXcel Therapeutics (BTAI) plans to submit a supplemental New Drug Application (sNDA) for IGALMI's at-home use in early Q1 2026. Given that BXCL501, the active ingredient in IGALMI, has been granted Fast Track designation by the FDA for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia, this could lead to an expedited review process.1

Here's an analysis of the potential implications for the FDA review timeline:

  • Fast Track Designation Benefits: Fast Track designation allows for more frequent interactions with the FDA and makes the application eligible for Priority Review, if relevant criteria are met. It also permits a "rolling review," where sections of the sNDA can be submitted and reviewed before the entire application is complete.2 However, the FDA's official review clock does not begin until the final section of the sNDA is submitted.2 It is important to note that Fast Track designation does not guarantee a faster development or regulatory review and approval process.2

  • Priority Review Timeline: If the sNDA is granted Priority Review, the FDA's performance goal is to complete its review within six months from the 60-day filing date (the date the FDA formally accepts the application for review).2

  • Standard Review Timeline: For context, a standard review for a non-New Molecular Entity (NME) sNDA typically has a goal of ten months from the submission receipt date.2

  • Potential Review Extension: Both Priority and Standard reviews can be extended by up to three additional months if the FDA requires or receives substantial new information.2

Projected Timeline for IGALMI's At-Home Use sNDA:

Assuming the sNDA is submitted early in Q1 2026 (e.g., January 2026):

  • FDA Filing Acceptance: The FDA typically has 60 days to determine if an application is sufficiently complete to permit substantive review and accept it for filing. This would place the filing acceptance around March 2026.2
  • Priority Review Decision (6 months): If granted Priority Review, an approval decision could potentially occur around September 2026.
  • With Potential Extension (3 months): Accounting for a possible three-month extension, an approval could be pushed to December 2026.

If the sNDA submission occurs later in Q1 2026 (e.g., March 2026), these dates would shift accordingly, potentially placing an approval decision as late as February 2027, assuming Priority Review and a potential extension. The FDA may also refer applications for novel drug products or those presenting difficult questions of safety or efficacy to an advisory committee, which could also influence the timeline.2 BioXcel has indicated positive feedback from pre-sNDA meetings with the FDA, suggesting the planned regulatory package should be sufficient.3

Rate this response:
0
Tilføj en kommentar eller stil et opfølgende spørgsmål
Fortæl os, hvad du har at sige. Du kan inkludere links, men ikke *bare* links. Del dine tankevækkende meninger. Brug Markdown .
Using Standard
Subscribe for smarter answers and premium data.
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista

© 2015-2026 Fintel Ventures LLC. All rights reserved. Fintel® is a registered trademark.

This website is provided “as is” without any representations or warranties, express or implied. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any financial matter you should consult an appropriate professional.

About Fintel
Features
Explore
Help Center